These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 25735223)

  • 1. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
    Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
    Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
    Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
    J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
    Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
    Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
    Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
    J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
    Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
    Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodistribution characteristics and SPECT imaging of (99m)Tc-RET and (99m)Tc-REG in human lung cancer xenografts.
    Xie WH; Zhang B; Wang LH; Liu CY; Chang C; Lei B; Wu YW
    Cancer Biother Radiopharm; 2015 Apr; 30(3):117-24. PubMed ID: 25714734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.
    Engfeldt T; Orlova A; Tran T; Bruskin A; Widström C; Karlström AE; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2007 May; 34(5):722-733. PubMed ID: 17146656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [
    Facca VJ; Al-Saden N; Ku A; Reilly RM
    Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Evaluation of
    Oroujeni M; Rinne SS; Vorobyeva A; Loftenius A; Feldwisch J; Jonasson P; Chernov V; Orlova A; Frejd FY; Tolmachev V
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.
    Engfeldt T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsen L; Wennborg A; Karlström AE; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1843-53. PubMed ID: 17565496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel multivalent (99m)Tc-labeled EG2-C4bpα antibody for targeting the epidermal growth factor receptor in tumor xenografts.
    Li C; Zhang Y; Wang L; Feng H; Xia X; Ma J; Yuan H; Gao B; Lan X
    Nucl Med Biol; 2015 Jun; 42(6):547-54. PubMed ID: 25779037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 99mTc-peptide-ZHER2:342 Affibody® molecule for in vivo molecular imaging.
    Zhang JM; Zhao XM; Wang SJ; Ren XC; Wang N; Han JY; Jia LZ
    Br J Radiol; 2014 Jan; 87(1033):20130484. PubMed ID: 24273251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
    McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
    J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.
    Orlova A; Tran TA; Ekblad T; Karlström AE; Tolmachev V
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):260-9. PubMed ID: 19771426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
    Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
    J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diversity of RGD radiotracers in monitoring antiangiogenesis of flavopiridol and paclitaxel in ovarian cancer xenograft-bearing mice.
    Yang G; Sun H; Kong Y; Hou G; Han J
    Nucl Med Biol; 2014; 41(10):856-62. PubMed ID: 25195014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
    Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
    J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An improved
    Khodadust F; Ahmadpour S; Aligholikhamseh N; Abedi SM; Hosseinimehr SJ
    Eur J Med Chem; 2018 Jan; 144():767-773. PubMed ID: 29291444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Potential Usefulness of
    Avan Z; Biabani Ardakani J; Talebpour Amiri F; Abedi SM; Hosseinimehr SJ
    Cancer Biother Radiopharm; 2022 Nov; 37(9):862-869. PubMed ID: 32898439
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of
    Rainone P; Riva B; Belloli S; Sudati F; Ripamonti M; Verderio P; Colombo M; Colzani B; Gilardi MC; Moresco RM; Prosperi D
    Int J Nanomedicine; 2017; 12():3447-3461. PubMed ID: 28496321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.